TransMedics Group (NASDAQ:TMDX) Stock Price Down 6.5%

TransMedics Group, Inc. (NASDAQ:TMDX) traded down 6.5% during mid-day trading on Tuesday . The stock traded as low as $146.10 and last traded at $146.86. 492,816 shares traded hands during mid-day trading, a decline of 40% from the average session volume of 826,797 shares. The stock had previously closed at $157.00.

Wall Street Analysts Forecast Growth

TMDX has been the topic of a number of recent research reports. Needham & Company LLC began coverage on TransMedics Group in a report on Wednesday, August 21st. They issued a “buy” rating and a $208.00 target price on the stock. Canaccord Genuity Group raised their target price on TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Stephens upped their price target on TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Robert W. Baird assumed coverage on TransMedics Group in a research note on Tuesday, September 24th. They issued an “outperform” rating and a $200.00 price objective for the company. Finally, Oppenheimer upped their target price on TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, TransMedics Group currently has an average rating of “Buy” and an average price target of $174.30.

TransMedics Group Stock Performance

The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. The stock has a market cap of $4.86 billion, a P/E ratio of -432.71 and a beta of 1.99. The firm’s 50-day moving average is $156.42 and its two-hundred day moving average is $132.63.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. The business had revenue of $114.30 million for the quarter, compared to the consensus estimate of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. TransMedics Group’s revenue for the quarter was up 117.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.03) EPS. As a group, research analysts expect that TransMedics Group, Inc. will post 1.23 EPS for the current year.

Insiders Place Their Bets

In related news, insider Anil P. Ranganath sold 4,289 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total value of $652,785.80. Following the transaction, the insider now directly owns 8,893 shares of the company’s stock, valued at approximately $1,353,514.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Anil P. Ranganath sold 4,289 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $152.20, for a total transaction of $652,785.80. Following the completion of the sale, the insider now directly owns 8,893 shares of the company’s stock, valued at approximately $1,353,514.60. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director James R. Tobin sold 20,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $159.33, for a total transaction of $3,186,600.00. Following the completion of the transaction, the director now owns 173,146 shares in the company, valued at $27,587,352.18. The disclosure for this sale can be found here. Insiders sold 61,247 shares of company stock valued at $9,650,880 over the last quarter. Insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

A number of hedge funds have recently modified their holdings of TMDX. Amalgamated Bank grew its stake in TransMedics Group by 6.7% during the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after buying an additional 70 shares during the last quarter. Pitcairn Co. raised its holdings in TransMedics Group by 1.5% during the 1st quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock worth $398,000 after purchasing an additional 78 shares during the last quarter. Signaturefd LLC increased its holdings in TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after purchasing an additional 93 shares during the last quarter. Arizona State Retirement System raised its holdings in TransMedics Group by 2.1% in the second quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock worth $1,379,000 after purchasing an additional 186 shares during the period. Finally, International Assets Investment Management LLC acquired a new position in TransMedics Group in the 2nd quarter worth $47,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.